NYSE:CVM CEL-SCI (CVM) Stock Price, News & Analysis → The Single Biggest Breakthrough of the Decade (From Porter & Company) (Ad) Free CVM Stock Alerts $1.29 0.00 (0.00%) (As of 10:00 AM ET) Add Compare Share Share Today's Range$1.27▼$1.3150-Day Range$1.18▼$1.7852-Week Range$1.04▼$3.23Volume9,867 shsAverage Volume317,555 shsMarket Capitalization$69.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get CEL-SCI alerts: Email Address Ad Porter & CompanyThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technology as well. In my new investigation, I detail why this technology is the single biggest breakthrough of the decade.Click here to watch it now. About CEL-SCI Stock (NYSE:CVM)CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.Read More CVM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVM Stock News HeadlinesJune 6, 2024 | businesswire.comDr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical AdvisorMay 22, 2024 | money.usnews.comCel-Sci Corp.May 21, 2024 | finance.yahoo.comCVM: Confirmatory Study ClarityMay 16, 2024 | businesswire.comCEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial ResultsMay 8, 2024 | msn.comCEL-SCI gains as FDA greenlights confirmatory study for MultikineMay 8, 2024 | businesswire.comCEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck CancerApril 23, 2024 | businesswire.comCEL-SCI Appoints Mario Gobbo to Its Board of DirectorsApril 16, 2024 | businesswire.comChannel V Media Expands Content Marketing Division; Names Gabriella Bock Director of ContentApril 15, 2024 | finance.yahoo.comCVM: Parallel Engagement on Four FrontsApril 12, 2024 | msn.comScientists produce in vitro model of cell differentiation during early facial developmentApril 9, 2024 | msn.comResearchers discover two vesicle fusion mechanisms while studying vesicle movement in living cellsApril 6, 2024 | seekingalpha.comCVM CEL-SCI CorporationMarch 28, 2024 | msn.comCross-species insights: Study finds calcium link in plant and animal immunityMarch 19, 2024 | stockhouse.comCEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 19, 2024 | finance.yahoo.comCEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in ImmunologyMarch 11, 2024 | msn.comResearchers reveal a new mechanism that regulates intestinal stem cellsMarch 6, 2024 | businesswire.comCEL-SCI Corporation Issues Letter to ShareholdersFebruary 23, 2024 | finance.yahoo.comCVM Apr 2024 4.000 callFebruary 15, 2024 | finance.yahoo.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 15, 2024 | businesswire.comCEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial ResultsFebruary 13, 2024 | finance.yahoo.comCEL-SCI Announces Closing of $7.75 Million Public Offering of Common StockFebruary 12, 2024 | seekingalpha.comCel-Sci: Fabulous Story Stock Works To Pass Muster With FDAFebruary 9, 2024 | msn.comWhy CEL-SCI Corporation (CVM) Shares Are DivingFebruary 9, 2024 | finance.yahoo.comCEL-SCI Announces Pricing of $7.75 Million Public Offering of Common StockFebruary 6, 2024 | stockhouse.comCEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer DrugSee More Headlines Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/14/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:CVM CUSIPN/A CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-218.00% Return on Assets-98.53% Debt Debt-to-Equity Ratio0.63 Current Ratio1.67 Quick Ratio1.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book4.64Miscellaneous Outstanding Shares54,160,000Free Float46,545,000Market Cap$70.41 million OptionableOptionable Beta1.04 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Geert R. Kersten Esq. (Age 65)Chief Executive & Financial Officer, Treasurer and Director Comp: $702.79kMs. Patricia B. Prichep (Age 73)Senior VP of Operations & Corporate Secretary Comp: $295.18kDr. Eyal Talor Ph.D. (Age 68)Chief Scientific Officer Comp: $351.88kDr. Daniel H. Zimmerman Ph.D. (Age 83)Senior Vice President of Research & Cellular Immunology Comp: $46.08kMr. John Cipriano (Age 82)Senior Vice President of Regulatory Affairs Comp: $246.97kKey CompetitorsGenfitNASDAQ:GNFTPoseida TherapeuticsNASDAQ:PSTXAdaptimmune TherapeuticsNASDAQ:ADAPCentury TherapeuticsNASDAQ:IPSCInnate PharmaNASDAQ:IPHAView All CompetitorsInsiders & InstitutionsVirtu Financial LLCSold 42,316 shares on 5/20/2024Ownership: 0.033%Tidal Investments LLCBought 13,891 shares on 5/17/2024Ownership: 0.026%Vanguard Group Inc.Bought 113,703 shares on 5/10/2024Ownership: 4.063%Geert R KerstenBought 30,000 shares on 5/8/2024Total: $41,700.00 ($1.39/share)Patricia B PrichepBought 8,000 shares on 5/8/2024Total: $11,120.00 ($1.39/share)View All Insider TransactionsView All Institutional Transactions CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed in 2024? CEL-SCI's stock was trading at $2.72 at the beginning of 2024. Since then, CVM stock has decreased by 52.2% and is now trading at $1.30. View the best growth stocks for 2024 here. How were CEL-SCI's earnings last quarter? CEL-SCI Co. (NYSE:CVM) announced its quarterly earnings data on Thursday, May, 16th. The company reported ($0.14) EPS for the quarter, meeting analysts' consensus estimates of ($0.14). When did CEL-SCI's stock split? CEL-SCI shares reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Who are CEL-SCI's major shareholders? CEL-SCI's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.06%), CVI Holdings LLC (1.63%), Thoroughbred Financial Services LLC (0.11%), Virtu Financial LLC (0.03%), Chilton Capital Management LLC (0.03%) and Tidal Investments LLC (0.03%). Insiders that own company stock include Bruno Jean-Marie Baillavoine, Eyal Talor, Geert R Kersten, Patricia B Prichep, Peter R Young and Robert Eugene Watson. View institutional ownership trends. How do I buy shares of CEL-SCI? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:CVM) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CEL-SCI Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share CEL-SCI With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.